Scientific Program - Retina

Please see below the COPHy Scientific Program. Please click on the appropriate section to view the relevant program. Please note that the program is subject to change. To view the program timetable / overview, please click here


Anterior Segment Glaucoma Other
FRIDAY, MARCH 31, 2017
 OCT-Angiography (OCT-A) and Ultrawide Field Imaging: Fads or Foundations of Ocular Imaging in 2017?
Chairs: Neil Bressler, USA and Hendrik Scholl, Switzerland
08:45-09:15 OCT-A should replace fluorescein angiography in the management of most cases of choroidal neovascular ("wet”) age-related macular degeneration
08:45-08:55 Yes: Alain Gaudric, France
08:55-09:05 No: Susan Bressler, USA
09:05-09:15 Discussion
09:15-09:45 Ultra-wide field imaging should be obtained if accessible for patients with diabetic retinopathy
09:15-09:25 Yes: James Talks, UK
09:25-09:35 No: Sobha Sivaprasad, United Kingdom
09:35-09:45 Discussion
09:45-10:15 OCT-A can be helpful as a prognostic factor in diabetic macular edema
09:45-09:55 Yes: Paolo Lanzetta, Italy
09:55-10:05 No: Jose Cunha-Vaz, Portugal
10:05-10:15 Discussion
10:15-10:45 Visit Exhibits and Refreshment Break
RETINA I | Non-neovascular ("Dry”) Age-related Macular Degeneration
Chairs: Susan Bressler, USA and Alfredo Garcia Layana, Spain
10:45-11:15 Genetic testing should be part of standard care in AMD
10:45-10:55 Yes: Alfredo Garcia Layana, Spain
10:55-11:05 No: Hendrik Scholl, Switzerland
11:05-11:15 Discussion
11:15-11:45 Dietary supplements such as those used in AREDS should be considered for patients with geographic atrophy in AMD
11:15-11:25 Yes: Michaella Goldstein, Israel
11:25-11:35 No: Marc de Smet, Switzerland
11:35-11:45 Discussion
11:45-12:15 Home monitoring beyond an Amsler grid should be standard care where accessible
11:45-11:55 Yes: Susan Bressler, USA
11:55-12:05 No: Paolo Lanzetta, Italy
12:05-12:15 Discussion
12:15-12:30 Visit Exhibits and Lunch Box Pick-up
Industry-sponsored Symposium
13:45-14:15 Visit Exhibits & Dessert Break
RETINA II | Diabetic Macular Edema (DME)
Chairs: Jean-Francois Korobelnik, France and Jose Cunha-Vaz, Portugal
14:15-14:45 Specific biomarkers (e.g., retinopathy severity or OCT findings) can predict response to treatment in diabetic macular edema independent of visual acuity at time of initiating treatment
14:15-14:25 Yes: Jose Cunha-Vaz, Portugal
14:25-14:35 No: Francesco Boscia, Italy
14:35-14:45 Discussion
14:45-15:15 In a patient with DME, phakic or pseudophakic, with sub-optimal response (<1-line [5-letter] improvement after three anti-VEGF injections, and persistent DME), treatment should be switched to corticosteroids
14:45-14:55 Yes: Barry Kupperman, USA
14:55-15:05 No: Susan Bressler, USA
15:05-15:15 Discussion
15:15-15:45 Start with bevacizumab, and if sub-optimal response (<1-line [5-letter] improvement after 3 anti-VEGF injections and persistent DME), switch to aflibercept for eyes with center-involved DME causing moderate to severe visual acuity loss
Yes: Patricia Udaondo, Spain
15:25-15:35 No: Jean-Francois Korobelnik, France
15:35-15:45 Discussion
Industry-sponsored Symposium
16:45-18:15 RETINA III | Surgical Controversies
Chairs: Francesco Boscia, Italy and Joseph Moisseiev, Israel
16:45-17:15 Typically use perfluorocarbon liquid with vitrectomy for rhegmatogenous RD
16:45-16:55 Yes: Stanislao Rizzo, Italy
16:55-17:05 No: Joseph Moisseiev, Israel
17:05-17:15 Discussion
17:15-17:45 Anti-coagulation therapy typically should be adjusted to prevent hemorrhagic complications during vitreoretinal surgery
17:15-17:25 Yes: Jose Garcia Arumii, Spain
17:25-17:35 No: Joseph Moisseiev, Israel
17:35-17:45 Discussion
17:45-18:15 Vitrectomy in uveitis is for diagnostic, not therapeutic purposes
17:45-17:55 Yes: William F. Mieler, USA
17:55-18:05 No: Jose Garcia Arumii, Spain
18:05-18:15 Discussion


07:30-08:30 Breakfast Session | Controversies in Geographic Atrophy of the RPE: Getting Closer to a Treatment?
Chairs: Neil Bressler, USA and Anat Loewenstein, Israel
07:30-07:35 Introduction and goals: Anat Loewenstein, USA
07:35-07:45 Imaging geographic atrophy: Hendrik Scholl, Switzerland
07:45-07:50 Questions
07:50-08:00 Role of dietary supplements for geographic atrophy: Susan Bressler, USA
08:00-08:05 Questions
08:05-08:15 What do we know about geographic atrophy from previous trials and rationale for phase 3 trials: Neil Bresssler, USA
08:15-08:20 Questions
08:20-08:30 Conclusions and Next Steps: Neil Bressler, USA and Anat Loewenstein, Israel
RETINA IV | Big Retina Controversies in 2017
Chairs: Susan Bressler, USA and Michaella Goldstein, Israel
09:00-09:30 Evidence is convincing that stem cells are viable treatment for geographic atrophy
09:00-09:10 Yes: Hendrik Scholl, Switzerland
09:10-09:20 No: Jay Ambati, USA
09:20-09:30 Discussion
09:30-10:00 Management of eyes receiving anti-VEGF for DME also should get PRP if proliferative diabetic retinopathy is present
09:30-09:40 Yes: Edouardo Midena, Italy
09:40-09:50 No: Bora Eldem, Turkey
09:50-10:00 Discussion
10:00-10:30 Incremental cost-effectiveness ratios (ICERs) preclude consideration of aflibercept for diabetic macular edema
10:00-10:10 Yes: Sobha Sivaprasad, UK
10:10-10:20 No: Jean-Francois Korobelnik, France
10:20-10:30 Discussion
10:30-10:45 Visit Exhibits & Coffee and Refreshment Break
RETINA V | Surgical Instrumentation Controversies
Chairs: William F. Mieler, USA and Stanislao Rizzo, Italy
10:45-11:03 High speed cutting probes (5000 and more) are important for outcomes
10:45-10:51 Yes: Stanislao Rizzo, Italy
10:51-10:57 No: Joseph Moisseiev, Israel
10:57-11:03 Discussion
11:03-11:21 27G vitrectomy is a substantial improvement over 25G vitrectomy
11:03-11:09 Yes: William F. Mieler, USA
11:09-11:15 No: Francesco Boscia, Italy
11:15-11:21 Discussion
11:21-11:39 3D display microscopes (heads up) are a paradigm change
11:21-11:27 Yes: William F. Mieler, USA
11:27-11:33 No: Alfredo Garcia Layana, Spain
11:33-11:39 Discussion
11:39-11:57 Intraoperative OCT is a game-changer
11:39-11:45 Yes; Stanislao Rizzo, Italy
11:45-11:51 No: Joseph Moisseiev, Israel
11:51-11:57 Discussion
11:57-12:15 Panel discussion: 2 case presentations
  Joseph Moisseiev, Israel and William F. Mieler, USA
12:15-12:30 Visit Exhibits & Lunch Box Pick-up
Industry-sponsored Symposium
13:45-14:15 Visit Exhibits & Dessert Break
RETINA VI | Neovascular ("Wet”) AMD Management
Chairs: Francesco Boscia, Italy and Sobha Sivaprasad, UK
15:45-16:15 Bevacizumab is as good as aflibercept for CNV from AMD
15:45-15:55 Yes: Francesco Boscia, Italy
15:55-16:05 No: Marta Figueroa, Spain
16:05-16:15 Discussion
16:15-16:45 Management of predominantly hemorrhagic lesions in AMD is more than anti-VEGF injections
16:15-16:25 Yes: Barry Kupperman, USA
16:25-16:35 No: Francesco Bandello, Italy
16:35-16:45 Discussion
16:45-17:15 Fluorescein angiography typically should be obtained before initiating anti-VEGF therapy for CNV in AMD
16:45-16:55 Yes: Bora Eldem, Turkey
16:55-17:05 No: Patricia Udaondo, Spain
17:05-17:15 Discussion